Major player in the funding of healthcare and biotechnology in Europe

We invest at various stages of maturity, from company creation to capital expansion

Major player in the funding of healthcare and biotechnology in Europe

We invest at various stages of maturity, from company creation to capital expansion

Major player in the funding of healthcare and biotechnology in Europe

We invest at various stages of maturity, from company creation to capital expansion

Crédit photo : Institut Pasteur

1. Our Vision

We have
high standards

We have built a strong network of partners with the best European academic research players, to transform their disruptive scientific discoveries into cutting-edge medicines or medical devices to diagnose and treat patients with severe diseases with high unmet medical need. 

We build
companies

Our ambition is to work with leading European research centers to build the healthcare industry of tomorrow.

In that perspective, we have developed a unique approach. We work closely with the research teams early on to define a plan to validate their discoveries and bring together the best healthcare industry experts and later the most experienced entrepreneurs to create high-tech companies.

We provide capital/funding to the companies we have founded with our funds and invite other investors to join us. This new and distinctive approach makes us stand out from most players in the world of healthcare investment and has enabled us to build more than 10 companies over the past 10 years.

We are also involved in early stage companies that have already been created, but always by supporting their development by providing our expertise and network.

We have thus contributed to the financing of more than 40 companies, many of which have become recognized leaders in their respective sectors.

We have
impact

Because of our business, we are players in the world of healthcare and as such are committed to making our contribution to sustainable development. We adhere to the ESG practices we have established


2. Our story

2009
Creation of Kurma Partners
by Thierry Laugel
2009
Closing of Kurma Biofund I
2011
Rémi Droller joins Kurma Partners
2012
Sylvain Cascarino joins Kurma Partners
2013
Closing of Kurma Biofund II
2013
Vanessa Malier joins Kurma Partners 
2015
Closing of Kurma Diagnostics 1
2015
Alain Horvais and Philippe Peltier
join Kurma Partners
2016
Kurma Partners majority owned by its partners
Partners acquired majority shareholding of the management company
2017
Delegate management of
Paris Saclay Seed Fund

2018
First closing of Kurma Biofund III

2019
Peter Neubeck joins Kurma Partners

2019
Opening of the office in Germany

2020
Final closing of Kurma Biofund III
2020
First closing of Kurma Diagnostics II
2020
Benjamin Belot joins Kurma Partners

 

3. Key data

42

companies financed
since 2009

24

companies founded
since 2009

470

million €
under management

800

employees in
companies financed 


 

4. Our partners

Kurma has created a solid network of partners to transform their most disruptive scientific discoveries into cutting-edge drugs or medical devices for the diagnosis and treatment of patients with severe diseases with high unmet medical need.

5. OUR PROACTIVE
ESG APPROACH

  • The raison d’être of Kurma Partners fits perfectly with a proactive impact and ethical policy.
     
  • Its willingness to respond to unmet medical needs contributes to ensuring the health of all (United Nations Sustainable Development Goal No. 3).
     
  • Kurma Partners developed an ESG charter in 2020 and will join the UN PRI. Kurma Partners reconciles investor and market expectations in terms of transparency and strong commitment.
     
  • A policy of vigilance with strict inclusion or exclusion criteria has been implemented with regard to any subject relating to medical bioethics.
     
  • In 2020, Kurma Partners is committed to develop an Ethics Charter for its portfolio companies.
     
  • By promoting the best ESG practices, Kurma Partners collects extra-financial data on all its portfolio companies via a questionnaire. Those information are consolidated in ESG section of each annual report.
     
 

X

X